Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06835387 · ClinicalTrials.gov registry record · Phase 2
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
A Phase 2 study of Small Bowel Adenocarcinoma, sponsored by Tiago Biachi de Castria.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT06835387: Recruiting Phase 2 study of Small Bowel Adenocarcinoma, sponsored by Tiago Biachi de Castria.
NCT06835387 is a Phase 2 study of Small Bowel Adenocarcinoma that is actively recruiting participants, run by Tiago Biachi de Castria. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06835387, a Phase 2 study of Small Bowel Adenocarcinoma, is actively recruiting participants, sponsored by Tiago Biachi de Castria.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
The study regimen will be administered on an outpatient basis and all medications are administered intravenously (IV). Subjects will receive treatment on Day 1 and Day 15 of each 28-day cycle consisting of the following: nanoliposomal irinotecan at 50 mg/m2, followed by oxaliplatin 60 mg/m2, followed by leucovorin at 400 mg/m2 30 minutes after completion of oxaliplatin, followed by 5-FU 2400 mg/m2 60 minutes after leucovorin completion. Subjects will receive up to 6 cycles of NALIRIFOX then based on response and per physician discretion, de-escalated maintenance treatment with NALIRIFOX minus oxaliplatin may continue. Subjects will continue de-escalated maintenance treatment until progression per RECIST 1.1, intolerable toxicity or physician/subject choice to discontinue.
Primary Outcome
ORR is defined as the proportion of subjects with a confirmed complete or partial response to treatment according to RECIST 1.1, by local assessment.
Conditions Studied
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Nanoliposomal irinotecan
- DRUG 5 fluorouracil
Study Locations (5)
Florida
- Moffitt Cancer Center - Tampa
Illinois
- University of Illinois Cancer Center - Chicago
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Atlantic Health System - Morristown
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
What NCT06835387 shows while recruiting
NCT06835387 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Small Bowel Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Leucovorin is the first listed.
NCT06835387 lists 5 locations in 5 states (Florida, Illinois, Missouri).
Frequently Asked Questions
What is clinical trial NCT06835387 about?
NCT06835387 is a clinical study titled "Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors". The study regimen will be administered on an outpatient basis and all medications are administered intravenously (IV). Subjects will receive treatment on Day 1 and Day 15 of each 28-day cycle consisting of the following: nanoliposomal irinotecan at 50 mg/m2, followed by oxaliplatin 60 mg/m2, followe...
What is the current status of trial NCT06835387?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2025-06-30. Estimated completion is 2028-08.
What conditions does trial NCT06835387 study?
This clinical trial studies the following conditions: Small Bowel Adenocarcinoma.
What interventions are being tested in trial NCT06835387?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), Nanoliposomal irinotecan (DRUG), 5 fluorouracil (DRUG).
Who is sponsoring clinical trial NCT06835387?
This trial is sponsored by Tiago Biachi de Castria, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06835387 being conducted?
This trial has 5 study locations across Florida, Illinois, Missouri, New Jersey, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06835387's enrollment target sits among peer trials
36 1496th of 2000 higher than 478 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI